Les Sulewski

How much of that was tied to product sales versus onetime channel stocking

can you quantify the regulatory pricing challenges you are seeing across the region

perhaps maybe give us an update, if you could, on the Indore resolution situation

one being the uptick in Lipitor, are you able to capture some of the share from the recent generic recall? And then second, what's driving the uptick in EpiPen